Amneal Pharmaceuticals, Inc. Class A Common Stock Capital Reinvestment Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock capital reinvestment ratio. Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Capital Reinvestment Ratio of 0.13x as of September 2025, meaning it reinvests 0% of its operating cash flow ($118.45 Million) in capital expenditures ($15.05 Million). Check AMRX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock (2014–2024)
Capital reinvestment ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2014 to 2024. This chart tracks Amneal Pharmaceuticals, Inc. Class A Common Stock's Capital Reinvestment Ratio across 11 annual periods. Also explore Amneal Pharmaceuticals, Inc. Class A Com net asset momentum to track the company's year-over-year net asset growth rate.
Amneal Pharmaceuticals, Inc. Class A Common Stock Capital Reinvestment Ratio by Year (2014–2024)
Amneal Pharmaceuticals, Inc. Class A Common Stock capital reinvestment ratio by year from 2014 to 2024. For the full cash flow conversion analysis, see AMRX operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.18x | $295.10 Million | $51.92 Million | ▼ -12.1% |
| 2023 | 0.20x | $345.58 Million | $69.19 Million | ▼ -85.6% |
| 2022 | 1.39x | $65.10 Million | $90.59 Million | ▲ +539.3% |
| 2021 | 0.22x | $241.82 Million | $52.64 Million | ▲ +24.6% |
| 2020 | 0.17x | $379.00 Million | $66.19 Million | ▼ -99.7% |
| 2019 | 57.14x | $1.71 Million | $97.43 Million | ▲ +14628.1% |
| 2018 | 0.39x | $250.23 Million | $97.09 Million | ▼ -20.5% |
| 2017 | 0.49x | $234.19 Million | $114.27 Million | ▼ -54.9% |
| 2016 | 1.08x | $115.06 Million | $124.61 Million | ▼ -3.2% |
| 2015 | 1.12x | $104.88 Million | $117.38 Million | ▲ +58.3% |
| 2014 | 0.71x | $112.26 Million | $79.38 Million | — |